Author/Authors :
Schroder، نويسنده , , Louis E and Lew، نويسنده , , Danika and Flanigan، نويسنده , , Robert C and Eisenberger، نويسنده , , Mario A and Seay، نويسنده , , Thomas E and Hammond، نويسنده , , Neel and Needles، نويسنده , , Burton M and Crawford، نويسنده , , E.David، نويسنده ,
Abstract :
Twenty-two eligible patients with advanced renal carcinoma were treated with suramin utilizing a fixed dose regimen. Therapy was reasonably well tolerated with 3 of 22 patients (14%) developing grade 4 toxicity and 11 of 22 patients (50%) having a maximum toxicity of grade 3. There were no responders; median survival was 10 months. Suramin is not an active agent in advanced renal carcinoma.
